Posted inPharmaceutical
Chronic Hepatitis B Treatment: What Hibsago Changes
Chronic hepatitis B treatment explained: who can use Hibsago, what trials showed on stopping medicine, and the boxed liver and platelet warning.
Posted inPharmaceutical
Esophageal Cancer Immunotherapy Explained: What JUPITER-06 Shows
Esophageal cancer immunotherapy explained: how toripalimab works, what JUPITER-06 showed on survival and side effects, and what India’s approval means.
Posted inPharmaceutical
Oral Inflammatory Bowel Disease Treatment: What Emvistegrast Shows
An oral inflammatory bowel disease treatment, emvistegrast, met its Phase 2 goal in ulcerative colitis. What the data show and cannot yet prove.
Posted inPharmaceutical
India Caps Trade Margins on 137 Cancer Drugs: What the NPPA Order Does
Cancer drug price cap India: how the NPPA 30% trade-margin order on 137 medicines works, its legal basis, and how it compares with 2019.
Posted inPharmaceutical
South Africa Plans New Rules for Compounded Weight-Loss Drugs
South Africa is drafting standards for compounded weight-loss drugs. A timeline of enforcement and what is legal today versus proposed.
Posted inPharmaceutical
Vanda’s Experimental Social Anxiety Drug VQW-765 Fails Phase 3 Trial Endpoint
VQW-765 Phase 3 trial: no difference from placebo on public-speaking distress (65.6 vs 66.0). Design, results, caveats and what happens next.
Posted inPharmaceutical
EMA Committee Recommends Rasonque for Metastatic Pancreatic Cancer After Phase 3 Survival Gain
Daraxonrasib pancreatic cancer: RASolute 302 shows 13.2 vs 6.7 months survival; the CHMP backs Rasonque. Trial design, side effects and caveats.
Posted inPharmaceutical
Zydus Sunshine Lifesciences Plans $20 Million-Plus Pharmaceutical Plant in Sri Lanka
Zydus international expansion reaches Sri Lanka: a $20M-plus plant via a joint venture, operations from 2028. How it is built and what is unclear.
Posted inPharmaceutical
First Tracks Reports Positive ANB033 Gluten-Challenge Results in Celiac Disease
ANB033 clinical trial: a CD122 antibody limited gluten-linked gut damage and symptoms in 32 celiac patients. Early data, key caveats.
Posted inPharmaceutical
BNT113 Clinical Trial Disappoints, but Survival Data Await
The BNT113 clinical trial missed its progression-free survival goal in HPV16-positive head and neck cancer. Overall survival analysis continues.